NCT01389466已完成1 期
Randomized Phase I/II Study to Evaluate the Safety and Immunogenicity of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 346
- 试验地点
- 4
- 主要终点
- Percentage of subjects achieving post-vaccination Hemagglutination Inhibition(HI) antibody titer ≥ 1:40 in each dose group
研究概览
简要总结
This study was designed in two steps with Step 1, a single-center, double-blind, randomized clinical Pilot study and Step 2, a multi-center, single-blind, randomized clinical Pivotal study. The investigator evaluate the immunogenicity and safety of the investigational vaccine in the subjects during their participation in the study.
详细描述
MG1109 is purified, inactivated influenza viral antigen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 58 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults who are available for follow-up during the study
排除标准
- •Subjects with history of exposure to the H5N1 subtype or H5N1 subtype vaccine
- •Subjects with immune system disorder including immune deficiency disease
结局指标
主要结局
Percentage of subjects achieving post-vaccination Hemagglutination Inhibition(HI) antibody titer ≥ 1:40 in each dose group
时间窗: 42 days after vaccination
Number of subjects with Solicited / Unsolicited adverse events
时间窗: With in 24 weeks after vaccination
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Phase I/II Study of KP-100IT in Acute Spinal Cord InjurySpinal Cord InjuriesNCT02193334Kringle Pharma, Inc.45
终止
1 期
A Study of MS-553 in Patients With Relapsed or Refractory B-cell LymphomaRelapsed or Refractory B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Marginal Zone Lymphoma (MZL)NCT05720052MingSight Pharmaceuticals, Inc8
招募中
1 期
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.Non-Small Cell Lung CancerNCT05937906Centre Georges Francois Leclerc24
招募中
1 期
Phase 1 Study of KH607 TabletsHealthyNCT06393803Chengdu Kanghong Pharmaceutical Group Co., Ltd.88
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy VolunteersHealthyNCT02819687Ardelyx80